Last edited by Mazulrajas
Tuesday, April 21, 2020 | History

1 edition of Clinical experiences with tolamolol, a cardioselective beta-blocking agent. found in the catalog.

Clinical experiences with tolamolol, a cardioselective beta-blocking agent.

Clinical experiences with tolamolol, a cardioselective beta-blocking agent.

  • 4 Want to read
  • 39 Currently reading

Published by Excerpta Medica in Amsterdam .
Written in English


Edition Notes

ContributionsLown, B. L.
ID Numbers
Open LibraryOL14450321M

The cardiac electrophysiological effects of sotalol were studied in ten patients (pts) aged 20‐65 years undergoing intracardiac stimulation studies for palpitations (7 pts) or dizzy spells (3 pts). The following measurements were made: 1. basic sinus cycle length (SCL); 2. sinus node recovery time (SNRT) following overdrive pacing; 3. intra‐atrial (PA), atrio‐His (AH) and His. The usual daily dosage is mg—25 mg hydrochlorothiazide combined with 25 mg— mg metoprolol succinate PO once daily. A mg hydrochlorothiazide/50 mg metoprolol dose can be achieved by splitting the mg hydrochlorothiazide/ mg metoprolol tablet.


Share this book
You might also like
Issues in economics today

Issues in economics today

value of public health dentistry

value of public health dentistry

Trades Councils guide

Trades Councils guide

Making a Nation

Making a Nation

Ryfka

Ryfka

Fields of grace

Fields of grace

Financial management in local government.

Financial management in local government.

Making the break.

Making the break.

History of Scottish Literature

History of Scottish Literature

Hans Frost

Hans Frost

Death of a Con Man

Death of a Con Man

Energy study

Energy study

Balzac and his world.

Balzac and his world.

Business strategy

Business strategy

Restoration scriptures

Restoration scriptures

A Victorian R. S. M.

A Victorian R. S. M.

Clinical experiences with tolamolol, a cardioselective beta-blocking agent. Download PDF EPUB FB2

The efficacy of tolamolol, a cardioselective beta adrenergic blocking agent, was evaluated in the treatment of cardiac arrhythmias in 27 patients. Nin Cited by: 7. Bioavailability of tolamolol. European Journal of Clinical Pharmacology9 (4), DOI: /BF A Williams, M C Holt.

An Assessment of the Anti-Anginal Effect of Tolamolol, a New Beta-Blocking Agent. Journal of International Medical Research3 (6), DOI: /Cited by:   Sandler G, Clayton GA. Clinical evaluation of practolol, a new cardioselective beta-blocking agent in angina pectoris.

Br Med J. May 16; 2 ()– [PMC free article] Sood NK, Havard CW. Effects of a new cardioselective beta-adrenergic blocker (tolamolol) on exercise tolerance in patients with angina pectoris. by: The effect of a new beta-adrenergic blocking agent tolamolol, has been examined in a Clinical experiences with tolamolol cross-over study in a cardioselective beta-blocking agent.

book patients suffering from angina pectoris. After a run-in period of four weeks, during which the patients received placebo, there were two a cardioselective beta-blocking agent.

book each of a cardioselective beta-blocking agent. book weeks when either tolamolol (– mg three times daily) or Cited by: 2. Tolamolol is a β-adrenergic blocking agent that has significant cardioselectivity in animals.

7 Fifty milligrams of tolamolol is equivalent to 40 mg of propranolol administered orally 8 and is an effective oral dose for the treatment of difficult tachyarrhythmias and digitalis-induced arrhythmias.9, 10 In order to assess the cardioselectivity Cited by: 6.

Recently, tolamolol and pamatolol, two cardioselective beta-adrenoreceptor blocking drugs, were withdrawn from Clinical experiences with tolamolol trials because they caused Clinical experiences with tolamolol tumors in mice and rats at high doses.

"5 Other beta-blockers-alprenolol and practololhave given some indication of tumorigenicity in rodents."Cited by: Most of the experience to date with beta-blockers in "thyroid storm" has been reported with propranolol.8' Beta blockers have also been used as a preoperative medication in thyrotoxic patients undergoing partial thyroidectomy.R-5 As part of the routine medical management, beta-blocking drugs are of less certain by: Cardioselective beta blockers have a clinical advantage in that they are 20 times more potent at blocking beta-1 receptors than beta-2 receptors.

They are therefore less likely to cause bronchoconstriction compared with non-selective beta-blockers; however, the danger of bronchoconstriction cannot be totally ignored, a cardioselective beta-blocking agent.

book they are not totally. The clinical importance of card ioselectivity and lipophilicity in beta blockers John M. Cruickshank, D.M., C.P.* Macclesfield, Cheshire, and Manchester, England Ever since Lands in proposed the existence of two types of beta receptor-beta-1 and beta2-it has been theoretically desirable for a beta blocker to possess the property of cardioselectivity, i.e., to Cited by: Abstract.

The variation in properties of beta adrenoceptor blocking drugs can be used as a basis for classification. There are those which are non-selective, those which have a selective action on the beta 1 receptors, and then those drugs which Clinical experiences with tolamolol addition possess vasodilator or alpha receptor blocking properties.

They may be further sub-divided into various groups according to the Cited by: Pindolol (A) is a beta2 blocker that can cause bronchoconstriction and increase asthmatic symptoms. Although carteolol (B) is a beta blocking agent and an effective antihypertensive agent used in managing angina, it can increase a client's risk for bronchoconstriction due to its nonselective beta blocker action.

Pharmacokinetic and physiological variables were measured in six healthy subjects after intravenous and oral administration of tolamolol. After intravenous injection of tolamolol (20 mg), a cardioselective beta-blocking agent.

book was a biphasic decline both in plasma concentration and attenuation of maximum exercise by: Sandler G, Clayton GA. Clinical evaluation of practolol, a new cardioselective beta-blocking agent in Clinical experiences with tolamolol pectoris.

Br Med J. May 16; 2 ()– [PMC free article] Sowton E, Balcon R, Cross D, Frick H. Haemodynamic effects of I.C.I. in patients with ischaemic heart disease. Br Med J. Jan 27; 1 ()–Cited by: 5. Beta blockers treat high blood pressure and other conditions, such as heart problems.

Learn why you might need them and their possible side effects. By Mayo Clinic Staff. Beta blockers, also known as beta-adrenergic blocking agents, are medications that reduce your blood pressure.

Beta blockers work by blocking the effects of the hormone. An older client is intolerant of decreased cardiac output which may cause dizziness and falls In an older client, cardiac output is decreased and a loss of contractility and elasticity reduces systemic and cerebral blood flow, so dysrhythmias, such as bradycardia or tachycardia is poorly tolerated, and increases the client's risk for syncope, falls, transient ischemic attacks, and possibly.

Robinson C, Birkhead J, Crook B, Jennings K, Jewitt D. Clinical electrophysiological effects of atenolol--a new cardioselective beta-blocking agent.

Br Heart J. Jan; 40 (1)– [PMC free article] Frankl WS, Soloff LA. Sotalol: a new, safe beta adrenergic receptor blocking agent. Am J Cardiol. Aug; 22 (2)–Cited by: Dose-response effects of cardioselective beta blockade in coronary artery disease Article (PDF Available) in Clinical Pharmacology & Therapeutics 36(1) August with 25 Reads.

Robinson C, Birkhead J, Crook B, Jennings K, Jewitt D. Clinical electrophysiological effects of atenolol--a new cardioselective beta-blocking agent. Br Heart J. Jan; 40 (1)– [PMC free article] Ruskin JN, Caracta AR, Akhtar M, Batsford WP, Damato AN. Electrophysiologic effects of tolamolol on atrioventricular conduction in by: The metabolism of tolamolol in the mouse, rat, Guinea-pig, rabbit, and dog.

Xenobiotica 5, – () PubMed Google Scholar Young, J.A., Edwards, K.D.G.: Studies on the absorption, metabolism, and excretion of methyldopa and other catechols and their influence on amino acid transport in rats.

by: Acute changes in renal function induced by bisoprolol, a new cardioselective beta-blocking agent Acute changes in renal function induced by bisoprolol, a new cardioselective beta-blocking agent Glück, Z.; Reubi, F.

Eur J Clin Pharrnacol () European Journal of Clinical Pharmacology © Springer-Verlag Z. Gltick and F. Beta-blocker therapy remains one of the most fascinating issues in heart failure (HF) clinical practice. These agents, once absolutely contraindicated in patients with HF, have been shown to have the greatest beneficial effects on the patients' : Marco Metra, Savina Nodari, Livio Dei Cas.

The haemodynamic effects of atenolol, a new cardioselective beta-blocking agent, have been studied at rest in 8 patients with coronary artery disease. The drug was administered intravenously in cumulative doses of, and mg/kg body weight.

A significant decrease in heart rate was associated with a fall in cardiac output. Atenolol, a cardioselective beta-blocking agent, at dose levels of, and mg/kg intravenously, produced prolongation of atrioventricular nodal conduction in 22 patients with.

Beta-adrenergic blocking agents are widely used to treat disorders of cardiac rhythm and rate, angina, and hypertension. Propranolol is the most widely used β-adrenergic blocking agent in this country. Because of its nonselective β-adrenergic blocking effect, propranolol may be associated with significant bronchoconstriction in asthmatic subjects and in some patients with chronic Cited by: 6.

Beta blockers (beta-blockers, β-blockers, etc.) are a class of medications that are predominantly used to manage abnormal heart rhythms, and to protect the heart from a second heart attack (myocardial infarction) after a first heart attack (secondary prevention).

They are also widely used to treat high blood pressure (hypertension), although they are no longer the first choice for ATC code: C   ZEBETA ® (bisoprolol fumarate) Tablets. DESCRIPTION. ZEBETA (bisoprolol fumarate) is a synthetic, beta 1-selective (cardioselective) adrenoceptor blocking chemical name for bisoprolol fumarate is (±)[4-[[2-(1- Methylethoxy)ethoxy]methyl]phenoxy][(1-methylethyl)amino]propanol(E)butenedioate () (salt).It possesses an asymmetric.

Answer: B) Hypotension Rationale: The primary adverse effects of alpha blockers are those related to their effects on the vasculature.

First-dose phenomenon, a severe and sudden drop in blood pressure after the administration of the fist dose of an alpha-adrenergic blocker, can cause patients to fall or pass out. Double-blind comparison of verapamil and practolol in the treatment of angina pectoris Article (PDF Available) in Postgraduate Medical Journal 53() March with 48 Reads.

Taylor's research works with 1, citations and reads, including: A critical assessment of a new computerized non-imaging echo-Doppler method. Abstract. The pharmacokinetic profile of an oral single dose of the new cardioselective beta-blocking agent, bisoprolol, was studied in patients with moderate and severe liver disease (Pugh group B and C, respectively) and normal by:   α- β1- and β2-adrenergic receptors in the kidney mediate vasoconstriction, renin secretion and vasodilatation, respectively.

Blockade of β-receptors may therefore be expected to influence renal blood flow and possibly glomerular filtration rate by intrarenal effects as well as by reducing cardiac output and blood pressure.

Since the various β-adrenergic blocking drugs Cited by:   Clearance of tolamolol from blood ranged from min 3. After the oral administration of tolamolol ( mg), the average volume of distribution was and plasma concentration half-life hours.

After ten eight-hourly doses of mg there was no accumulation of tolamolol and the half-life of plasma clearance was unchanged. Verma's 99 research works with citations and 1, reads, including: Hemodynamic interactions of a new beta blocker, celiprolol, with nifedipine in angina pectoris.

Patients with bronchospastic disease, should, in general, not receive beta blockers, including cardioselective beta-blockers. Because of the relative beta-1 selectivity, cardioselective beta-blockers may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment.

European Journal of Clinical Pharmacology. All Volumes & Issues. Vol Issue 3, (15 articles) Originals. Treatment of hypertension successively with a diuretic, clonidine or a beta-blocking agent and hydralazine. Pitkäjärvi Human experience of cetiedil, a new vasodilator with anticholinergic properties.

α 1-blockers act on α 1-adrenoceptors; α 2-blockers act on α 2-adrenoceptors; When the term "alpha blocker" is used without further qualification, it can refer to an α 1 blocker, an α 2 blocker, a nonselective blocker (both α 1 and α 2 activity), or an α blocker with some β activity.

However, the most common type of alpha blocker is usually an α 1 blocker. Non-selective α Biological target: α-adrenoceptors. Beta blockers are usually tolerated well without significant side effects. They may cause cold hands and feet, particularly in older people, and may also be associated with unusually vivid dreams.

Some patients experience fatigue, perhaps related to excessive slowing of the heart rate. Erectile dysfunction is occasionally a problem for some men. Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.

In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent/ A (Betaxolol Hydrochloride 10 mg) Pill with imprint A is White, Round and has been identified as Betaxolol Hydrochloride 10 mg.

It is supplied by Amide Pharmaceutical Inc. Betaxolol is used in the treatment of angina pectoris prophylaxis; high blood pressure and belongs to the drug class cardioselective beta cannot be ruled out during pregnancy. Acute Therapy of Supraventricular Arrhythmias in the Pregnant Woman Narrow-QRS-complex Tachycardia Narrow-QRS-complex tachycardia is a cardiac rhythm with a rate faster than bpm and a QRS duration of less than s.

21 The patient with narrow-QRS-complex tachycardia usually seeks medical attention because of palpitations, light-headedness Author: Hans-Joachim Trappe.

Propranolol, sold under the brand name Inderal among others, pdf a medication of pdf beta blocker class. It is used to treat high blood pressure, a number of types of irregular heart rate, thyrotoxicosis, capillary hemangiomas, performance anxiety, and essential tremors.

It is used to prevent migraine headaches, and to prevent further heart problems in those with angina or Metabolism: Liver (extensive) 1A2, 2D6; .PDR Drug Summaries are concise point-of-care prescribing, dosing and administering information to help phsyicans more efficiently and accurately prescribe in their practice PDR's drug summaries are available free of charge and serve as a great resource for US based MDs, DOs, NPs and PAs in patient practice.We studied 12 ebook with crisis of paroxysmal reciprocating supraventricular tachycardia before and after ebook injection of 5 mg of atenolol.

The patients were then followed for periods ranging from 6 to 50 months (median 34 months). During this time, they received oral atenolol therapy, at mg for the first two weeks, and mg daily thereafter. Tachycardia was due .